Agricultural University of Athens
Μελέτη RANKL-επαγόμενων παθογενετικών μηχανισμών σε γενετικά ζωικά πρότυπα και νέες θεραπευτικές προσεγγίσεις
Abstract
dc:descriptionBone remodeling is a continuous process of renewal of the bone by sequentialactivation and function of osteoclasts and osteoblasts, cells responsible for boneresorption and production, respectively. Normally, both processes are in dynamicequilibrium with each other, ensuring the skeletal integrity. Disruption of this balanceis the primary cause of skeletal diseases, such as osteoporosis. The cytokine RANKL(Receptor Activator of Nuclear Factor kB Ligand), a TNF superfamily member(Tumor Necrosis Factor), is the main mediator in the process of bone resorption as itinduces differentiation, survival and activity of osteoclasts. As trimer RANKL bindsto its receptor, RANK, induces trimerization and activation of intracellular pathwaysleading to the generation of mature and functional osteoclasts, while the action ofRANKL is inhibited by osteoprotegerin (OPG), a soluble decoy receptor. The ratiobetween RANKL and OPG determines the availability and activity of RANKL inbiological systems. The significance of RANKL in bone biology derives from theevidences that mutations in the RANKL gene lead to autosomal recessiveosteopetrosis due to lack of osteoclasts. Conversely, increased production of RANKLis linked to excess osteoclast activity and bone loss diseases, such as osteoporosis,rheumatoid arthritis, multiple myeloma, bone metastases and periodontal diseases. The inhibition of RANKL is considered a promising therapeutic approach for theprevention of bone loss diseases and it has already been approved, through theadministration of a monoclonal antibody against RANKL (denosumab), inpostmenopausal osteoporosis, and in men with bone metastases derived from theprostate. This makes it necessary to find new inhibitors of RANKL and evaluate themin appropriate animal models.Within the present PhD Thesis we studied two new animal models which have beencreated by the research team of the Assistant Professor Eleni Douni. The first geneticmodel is characterized by autosomal recessive osteopetrosis due to a point mutation inthe mouse RANKL gene that causes an amino acid substitution from glycine toarginine at position 278, (G278R) making the RANKL protein inactive (Douni et al.2012). The study of the responsible mutation has led to the understanding of themolecular pathogenesis and design of new inhibitors against RANKL. In particularwe showed by immunoblot experiments and cross-linking of RANKLG278R that themutant protein does not form homotrimers and has lost its biological activity. Inaddition, the RANKLG278R does not induce osteoclast formation and exerts a dominant negative effect on the activity of wild type mouse RANKL. The amino acid glycine atposition 278 shows high conservation among the members of the TNF superfamily.Βy introducing the corresponding amino acid change, from glycine to arginine, inhuman TNF and BAFF proteins, we have shown that the mutant TNFG122R andBAFFG249R proteins do not form trimers and are biologically inactive. The recognitionof such an amino acid that is actively involved in the trimerization of the TNFsuperfamily members constitutes a potentially drug target for the rational design ofnew drugs that disrupt trimerization. The SPD-304 has been identified as smallmolecule inhibitor of TNF trimerization but its activity against RANKL wasunknown. We showed that SPD-304 interacts with RANKL inducingosteoclastogenesis inhibition. However, the high toxicity of SPD-304 makes itunsuitable for pharmaceutical use. So, we designed and synthesized 72 newcompounds depending on SPD-304 structure, 7 of which have been identified with thefollowing characteristics: 1) inhibit RANKL-induced osteoclastogenesis, 2) exhibitconsiderably less cytotoxicity compared with the SPD-304, and 3) display highspecificity to the target protein RANKL. Biochemical assays showed that such inhibitors disrupt the trimer formation of RANKL. The evaluation of these potentsmall molecule inhibitors of RANKL in preclinical level presupposes the use ofappropriate animal models of osteoporosis.In this context, we developed and characterized novel genetic models of osteoporosisby overexpression of human RANKL in transgenic mice. We characterized twotransgenic lines, the Tg5516 transgenic line that carries one copy of the transgene andthe Tg5519 line with ten extra copies. Quantitative analysis of huRANKL geneshowed expression in the Tg5516 mice with even higher levels in the Tg5519 micemainly in bone, spleen and brain. Moreover, the overexpression of the huRANKL inboth transgenic lines follows the same pattern of expression of the endogenous gene(muRANKL). Phenotypic characterization showed that the Tg5516 line represents amild model of osteoporosis with bone loss of trabecular bone, while the Tg5519 linedevelops severe osteoporosis characterized by complete loss of trabecular bone,cortical porosity, increased osteoclastogenesis, progressive destruction of the growthplate and increased bone marrow adiposity. Finally, upon the effective therapy ofosteoporosis in Tg5519 mice with denosumab, we concluded that the TgRANKL mice are appropriate models of osteoporosis for the preclinical evaluation of newdrugs, such as the SPD-304 analogues.
Degree
thesis:*- Grantor dc:publisher
- Agricultural University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Rinotas, Vangelis
- Ρηνώτας, Ευάγγελος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38366